MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation

Seminars in Cancer Biology

Volumn 21, Issue 4, 2011, Pages 283-290

  Stallings, Raymond L ^a,b   Foley, Niamh H ^a,b   Bray, Isabella M ^a,b   Das, Sudipto ^a,b   Buckley, Patrick G ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

ATRA; Differentiation; DNA methylation; MicroRNA; MYCN; NCOR2; Neuroblastoma; NOS1

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; ISOTRETINOIN; MICRORNA; MICRORNA 10A; MICRORNA 10B; MICRORNA 124A; MICRORNA 125A; MICRORNA 125B; MICRORNA 128; MICRORNA 152; MICRORNA 184; MICRORNA 18A; MICRORNA 19A; MICRORNA 214; MICRORNA 26A; MICRORNA 26B; MICRORNA 7; MICRORNA 9; NEUROTROPHIN 3 RECEPTOR; NUCLEAR RECEPTOR COREPRESSOR; PROTEIN BCL 2; REELIN; RETINOIC ACID; RETINOID X RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; CANCER CELL CULTURE; CANCER SURVIVAL; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; EXON SKIPPING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION INITIATION; UNDIFFERENTIATED CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; DNA METHYLATION; HUMANS; MICRORNAS; NEUROBLASTOMA; TRETINOIN;

EID: 80655127778     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.07.001     Document Type: Review

References (71)

1. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3:203-216.
2. Stallings R.L. Are chromosomal imbalances important in cancer?. Trends Genet 2007, 23:278-283.
3. Janoueix-Lerosey I., Schleiermacher G., Michels E., Mosseri V., Ribeiro A., Lequin D., et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009, 27:1026-1033.
4. Oberthuer A., Berthold F., Warnat P., Hero B., Kahlert Y., Spitz R., et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006, 24:5070-5078.
5. Vermeulen J., De Preter K., Laureys G., Speleman F., Vandesompele J. 59-gene prognostic signature sub-stratifies high-risk neuroblastoma patients. Lancet Oncol 2009, 10:1030.
6. Bray I., Bryan K., Prenter S., Buckley P.G., Foley N.H., Murphy D.M., et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 2009, 4:e7850.
7. Mestdagh P., Fredlund E., Pattyn F., Schulte J.H., Muth D., Vermeulen J., et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010, 29:1394-1404.
8. Schulte J.H., Horn S., Otto T., Samans B., Heukamp L.C., Eilers U.C., et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 2008, 122:699-704.
9. Shimada H., Umehara S., Monobe Y., Hachitanda Y., Nakagawa A., Goto S., et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001, 92:2451-2461.
10. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341:1165-1173.
11. Abemayor E., Sidell N. Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. Environ Health Perspect 1989, 80:3-15.
12. Altucci L., Leibowitz M.D., Ogilvie K.M., de Lera A.R., Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007, 6:793-810.
13. Noy N. Between death and survival: retinoic acid in regulation of apoptosis. Annu Rev Nutr 2010, 30:201-217.
14. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522-531.
15. Kim V.N. Small RNAs: classification, biogenesis, and function. Mol Cells 2005, 19:1-15.
16. Orom U.A., Nielsen F.C., Lund A.H. MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008, 30:460-471.
17. Duursma A.M., Kedde M., Schrier M., le Sage C., Agami R. miR-148 targets human DNMT3b protein coding region. RNA 2008, 14:872-877.
18. Baek D., Villen J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
19. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318:1931-1934.
20. Place R.F., Li L.C., Pookot D., Noonan E.J., Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A 2008, 105:1608-1613.
21. Breving K., Esquela-Kerscher A. The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 2009, 42:1316-1329.
22. Garzon R., Calin G.A., Croce C.M. MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179.
23. Wang S., Olson E.N. AngiomiRs-key regulators of angiogenesis. Curr Opin Genet Dev 2009, 19:205-211.
24. Calin G.A. MicroRNAs and cancer: what we know and what we still have to learn. Genome Med 2009, 1:78.
25. Stallings R.L. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des 2009, 15:456-462.
26. Stallings R.L., Foley N.H., Bryan K., Buckley P.G., Bray I. Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets 2010, 14:951-962.
27. Eggert A., Schulte J.H. A small kiss of death for cancer. Nat Med 2010, 16:1079-1081.
28. Chen Y., Stallings R.L. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007, 67:976-983.
29. Lin R.J., Lin Y.C., Chen J., Kuo H.H., Chen Y.Y., Diccianni M.B., et al. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 2010, 70:7841-7850.
30. Schulte J.H., Schowe B., Mestdagh P., Kaderali L., Kalaghatgi P., Schlierf S., et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 2010, 127:2374-2385.
31. Bray I., Tivnan A., Bryan K., Foley N.H., Watters K.M., Tracey L., et al. MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 2011, 303:56-64.
32. Foley N.H., Bray I.M., Tivnan A., Bryan K., Murphy D.M., Buckley P.G., et al. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 2010, 9:83.
33. Fontana L., Fiori M.E., Albini S., Cifaldi L., Giovinazzi S., Forloni M., et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008, 3:e2236.
34. Tivnan A., Foley N.H., Tracey L., Davidoff A.M., Stallings R.L. MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma. Anticancer Res 2010, 30:4391-4395.
35. Tivnan A., Tracey L., Buckley P.G., Alcock L.C., Davidoff A.M., Stallings R.L. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer 2011, 11:33.
36. Welch C., Chen Y., Stallings R.L. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007, 26:5017-5022.
37. Beveridge N.J., Tooney P.A., Carroll A.P., Tran N., Cairns M.J. Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cell Signal 2009, 21:1837-1845.
38. Chen H., Shalom-Feuerstein R., Riley J., Zhang S.D., Tucci P., Agostini M., et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem Biophys Res Commun 2010, 394:921-927.
39. Foley N.H., Bray I., Watters K.M., Das S., Bryan K., Bernas T., et al. MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ 2011, 18:1089-1098.
40. Le M.T., Xie H., Zhou B., Chia P.H., Rizk P., Um M., et al. MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol 2009, 29:5290-5305.
41. Meseguer S., Mudduluru G., Escamilla J.M., Allgayer H., Barettino D. Micro-RNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF). J Biol Chem 2010.
42. Ragusa M., Majorana A., Banelli B., Barbagallo D., Statello L., Casciano I., et al. MIR152, MIR200B, and MIR338, human positional and functional neuroblastoma candidates, are involved in neuroblast differentiation and apoptosis. J Mol Med 2010, 88:1041-1053.
43. Thiele C.J., Reynolds C.P., Israel M.A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985, 313:404-406.
44. Murphy D.M., Buckley P.G., Bryan K., Das S., Alcock L., Foley N.H., et al. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One 2009, 4:e8154.
45. Edsjo A., Holmquist L., Pahlman S. Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation. Semin Cancer Biol 2007, 17:248-256.
46. Henriksen J.R., Haug B.H., Buechner J., Tomte E., Lokke C., Flaegstad T., et al. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma. BMC Dev Biol 2011, 11:1.
47. Negroni A., Scarpa S., Romeo A., Ferrari S., Modesti A., Raschella G. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ 1991, 2:511-518.
48. Tonelli R., Purgato S., Camerin C., Fronza R., Bologna F., Alboresi S., et al. Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. Mol Cancer Ther 2005, 4:779-786.
49. Edsjo A., Nilsson H., Vandesompele J., Karlsson J., Pattyn F., Culp L.A., et al. Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation. Lab Invest 2004, 84:406-417.
50. Laneve P., Di Marcotullio L., Gioia U., Fiori M.E., Ferretti E., Gulino A., et al. The interplay between microRNAs the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci U S A 2007, 104:7957-7962.
51. Thiele C.J., Israel M.A. Regulation of N-myc expression is a critical event controlling the ability of human neuroblasts to differentiate. Exp Cell Biol 1988, 56:321-333.
52. Laneve P., Gioia U., Andriotto A., Moretti F., Bozzoni I., Caffarelli E. A minicircuitry involving REST and CREB controls miR-9-2 expression during human neuronal differentiation. Nucleic Acids Res 2010, 38:6895-6905.
53. Makeyev E.V., Zhang J., Carrasco M.A., Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell 2007, 27:435-448.
54. Schulte J.H., Schowe B., Mestdagh P., Kaderali L., Kalaghatgi P., Schlierf S., et al. Accurate prediction of neuroblastoma outcome based on mirna expression profiles. Int J Cancer 2010.
55. Loven J., Zinin N., Wahlstrom T., Muller I., Brodin P., Fredlund E., et al. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci U S A 2010, 107:1553-1558.
56. Evangelisti C., Florian M.C., Massimi I., Dominici C., Giannini G., Galardi S., et al. MiR-128 up-regulation inhibits Reelin D.C.X. expression reduces neuroblastoma cell motility invasiveness. FASEB J 2009, 23:4276-4287.
57. Guidi M., Muinos-Gimeno M., Kagerbauer B., Marti E., Estivill X., Espinosa-Parrilla Y. Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. BMC Mol Biol 2010, 11:95.
58. Gao C.F., Xie Q., Su Y.L., Koeman J., Khoo S.K., Gustafson M., et al. Proliferation invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A 2005, 102:10528-10533.
59. Weiss F.U., Marques I.J., Woltering J.M., Vlecken D.H., Aghdassi A., Partecke L.I., et al. Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology 2009, 137:2136-2145. e1-7.
60. Das S., Foley N., Bryan K., Watters K.M., Bray I., Murphy D.M., et al. MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res 2010, 70:7874-7881.
61. Love W.K., Berletch J.B., Andrews L.G., Tollefsbol T.O. Epigenetic regulation of telomerase in retinoid-induced differentiation of human leukemia cells. Int J Oncol 2008, 32:625-631.
62. Rowling M.J., McMullen M.H., Schalinske K.L. Vitamin A and its derivatives induce hepatic glycine N-methyltransferase and hypomethylation of DNA in rats. J Nutr 2002, 132:365-369.
63. Monk M., Boubelik M., Lehnert S. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. Development 1987, 99:371-382.
64. Wu S.C., Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 2010, 11:607-620.
65. Pogribny I.P., Beland F.A. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci 2009, 66:2249-2261.
66. Buckley P.G., Das S., Bryan K., Watters K.M., Alcock L., Koster J., et al. Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer 2010, 128:2296-2305.
67. Bredt D.S., Snyder S.H. Transient nitric oxide synthase neurons in embryonic cerebral cortical plate, sensory ganglia, and olfactory epithelium. Neuron 1994, 13:301-313.
68. Ciani E., Severi S., Contestabile A., Bartesaghi R. Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. J Cell Sci 2004, 117:4727-4737.
69. Goll M.G., Bestor T.H. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005, 74:481-514.
70. Hermann A., Goyal R., Jeltsch A. The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites. J Biol Chem 2004, 279:48350-48359.
71. Huang J., Wang Y., Guo Y., Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010, 52:60-70.